Qualigen Therapeutics (QLGN)
(Delayed Data from NSDQ)
$5.53 USD
+2.69 (94.72%)
Updated Sep 22, 2025 04:00 PM ET
After-Market: $5.28 -0.25 (-4.52%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
QLGN 5.53 +2.69(94.72%)
Will QLGN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for QLGN based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for QLGN
12 Health Care Stocks Moving In Monday's Intraday Session
Crypto Currents: BitGo files for IPO as companies pivot to crypto
Crypto Currents: BitGo files for IPO as companies pivot to crypto
Gold Gains Over 1%; Quantum Computing Shares Plunge
Dow Falls Over 100 Points; Chicago Fed National Activity Index Rises In August